Research
10
minutes to read
January 31, 2025

Solvemed’s AI-Powered Pupillometry: A Breakthrough in Standardized Neurological Assessments at ISC 2025

Dr Michal Wlodarski
Chief Operating Officer, Co-founder

At the upcoming International Stroke Conference (ISC) 2025 in Los Angeles, Solvemed is set to unveil its ground-breaking AI Pupillometry System, showcasing key advancements in objective neurological assessment. One of the highlights of this presentation is the Pupil Reactivity (PuRe) score, a revolutionary AI-driven metric designed to standardize pupil reactivity assessments in clinical settings.

The Challenge of Traditional Pupillometry

Current pupillometry techniques face significant inconsistencies due to variables such as ambient lighting, while software pupillometers can face additional difficulties due to varied device models, and measurement distances. These factors can lead to unreliable neurological evaluations, particularly in critical care settings where precision is paramount.

Introducing the Invariant Pupil Reactivity (PuRe) Score

Solvemed’s PuRe score addresses these limitations by ensuring lighting-invariant, device-independent, and distance-agnostic pupillary assessments. The AI-driven approach integrates:

  • Adaptive algorithms to adjust flash intensity dynamically.
  • Real-time positioning guidance for optimal measurements.
  • Validation across a broad range of lighting conditions (5 - 11,800 lux) and different iPhone models (SE2, 13, and 15 Pro) at varying distances (50 - 210 mm).

Key Findings from the Study

Two investigations confirmed PuRe score reliability

PuRe Score remains stable across all tested conditions, eliminating traditional inconsistencies observed in manual and early digital pupillometry systems. This ensures that healthcare professionals can detect and monitor neurological deterioration with greater accuracy and reliability.

Transforming Neurological Assessments

By setting a new benchmark in standardized pupillary assessments, Solvemed’s innovation enhances clinical decision-making in stroke care and neurocritical monitoring. As ISC 2025 approaches, this breakthrough promises to reshape the future of neurological diagnostics and equip medical professionals with cutting-edge tools for enhanced patient care.

Follow us on LinkedIn and X to keep up-to-date with Solvemed at ISC 2025 as we continue to push the boundaries of AI-driven medical diagnostics.

Dr Michal Wlodarski
Chief Operating Officer, Co-founder
Sources: